VRAX vs. MYMD, NAVB, IDXX, LNTH, QDEL, NEOG, CLDX, NTLA, MYGN, and ACHV
Should you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include MyMD Pharmaceuticals (MYMD), Navidea Biopharmaceuticals (NAVB), IDEXX Laboratories (IDXX), Lantheus (LNTH), QuidelOrtho (QDEL), Neogen (NEOG), Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), and Achieve Life Sciences (ACHV). These companies are all part of the "diagnostic substances" industry.
Virax Biolabs Group (NASDAQ:VRAX) and MyMD Pharmaceuticals (NASDAQ:MYMD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends, community ranking and earnings.
MyMD Pharmaceuticals has lower revenue, but higher earnings than Virax Biolabs Group.
Virax Biolabs Group has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500.
Virax Biolabs Group's return on equity of 0.00% beat MyMD Pharmaceuticals' return on equity.
8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 9.6% of MyMD Pharmaceuticals shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by company insiders. Comparatively, 2.6% of MyMD Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Virax Biolabs Group and Virax Biolabs Group both had 2 articles in the media. MyMD Pharmaceuticals' average media sentiment score of 1.44 beat Virax Biolabs Group's score of 1.28 indicating that MyMD Pharmaceuticals is being referred to more favorably in the news media.
Virax Biolabs Group and MyMD Pharmaceuticals both received 0 outperform votes by MarketBeat users.
Summary
Virax Biolabs Group and MyMD Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.
Get Virax Biolabs Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Virax Biolabs Group Competitors List
Related Companies and Tools
